MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Artivion Inc

Geschlossen

BrancheGesundheitswesen

42.63 -3.62

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

42.63

Max

43.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

-14M

6.5M

Verkäufe

416K

113M

Gewinnspanne

5.734

Angestellte

1,600

EBITDA

2.6M

19M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+15.3% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-43M

2.1B

Vorheriger Eröffnungskurs

46.25

Vorheriger Schlusskurs

42.63

Nachrichtenstimmung

By Acuity

50%

50%

173 / 370 Ranking in Healthcare

Artivion Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Jan. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. Jan. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. Jan. 2026, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. Jan. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. Jan. 2026, 20:54 UTC

Ergebnisse

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. Jan. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. Jan. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. Jan. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. Jan. 2026, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. Jan. 2026, 19:22 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. Jan. 2026, 18:21 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. Jan. 2026, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. Jan. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. Jan. 2026, 18:16 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. Jan. 2026, 18:01 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. Jan. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer-Vergleich

Kursveränderung

Artivion Inc Prognose

Kursziel

By TipRanks

15.3% Vorteil

12-Monats-Prognose

Durchschnitt 51.71 USD  15.3%

Hoch 58 USD

Tief 40 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Artivion Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

6

Buy

1

Halten

0

Sell

Stimmung

By Acuity

173 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat